Desoxyribonuclease API Manufacturers
compare suppliers & get competitive offers
Join our notification list by following this page.
Click the button below to find out more
Click the button below to switch over to the contract services area of Pharmaoffer.
Looking for Desoxyribonuclease API 9003-98-9?
- Description:
- Here you will find a list of producers, manufacturers and distributors of Desoxyribonuclease. You can filter on certificates such as GMP, FDA, CEP, Written Confirmation and more. Send inquiries for free and get in direct contact with the supplier of your choice.
- API | Excipient name:
- Desoxyribonuclease
- Synonyms:
- Bovine pancreatic deoxyribonuclease , Deoxyribonuclease A , Deoxyribonuclease bovine pancreas , Deoxyribonuclease I , Deoxyribonuclease I bovine , Deoxyribonuclease, bovine , Dinase , Pancreatic dornase
- Cas Number:
- 9003-98-9
- DrugBank number:
- DB09551
- Unique Ingredient Identifier:
- 0BE71HM000
General Description:
Desoxyribonuclease, identified by CAS number 9003-98-9, is a notable compound with significant therapeutic applications. Desoxyribonuclease is a crystalline enzyme that aids in the digestion of the thymus nucleic acid. The mechanism of action of the enzyme involves the splitting of thymus nucleic acid into fragments approaching the size of tetranucleotides without the release of free phosphoric acid. The enzyme's cofactor is reported to be magnesium (or manganese) ions, although the optimal concentration of the ion is independent of the enzyme concentration .
Categories:
Desoxyribonuclease is categorized under the following therapeutic classes: Blood and Blood Forming Organs, Deoxyribonucleases, Enzymes, Enzymes and Coenzymes, Esterases, Hydrolases. These classifications highlight the drug's diverse therapeutic applications and its importance in treating various conditions.
Desoxyribonuclease is a type of Hematological Agents
Hematological agents, belonging to the pharmaceutical API category, are a vital class of drugs used in the treatment of various blood disorders and hematological conditions. These agents play a crucial role in managing diseases related to the blood and its components, such as red blood cells, white blood cells, platelets, and plasma.
One significant application of hematological agents is in the treatment of anemia, a condition characterized by a low red blood cell count or hemoglobin level. Hematopoietic growth factors, a subclass of hematological agents, stimulate the production of red blood cells and enhance their maturation, thereby addressing anemia.
Another area where hematological agents demonstrate their therapeutic potential is in the treatment of blood cancers, such as leukemia, lymphoma, and multiple myeloma. These agents, including chemotherapy drugs and targeted therapies, help suppress the abnormal growth of cancer cells and restore normal blood cell production.
Hematological agents also find application in managing bleeding disorders, such as hemophilia and thrombocytopenia. They work by promoting blood clotting and preventing excessive bleeding. Additionally, certain hematological agents function as immunosuppressants, playing a crucial role in hematopoietic stem cell transplantation and preventing graft-versus-host disease.
Overall, hematological agents form a vital category within the pharmaceutical API domain, offering targeted treatments for a range of blood disorders and playing a significant role in improving the quality of life for patients with hematological conditions.
